Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Provention Bio, Inc. - Common Stock (NQ: PRVB )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Provention Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (... 
Via Benzinga
Provention Bio, inc (PRVB) Q3 2021 Earnings Call Transcript
PRVB earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Provention Bio Reveals Early Data For Coxsackievirus B Vaccine Candidate
Provention Bio Inc (NASDAQ: PRVB) has announced interim results from the PROVENT Phase 1 trial of PRV-101. PRV-101 is a polyvalent inactivated coxsackievirus B (... 
Via Benzinga
Precigen Posts Additional Interim Data From Type 1 Diabetes Trial
Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio has announced additional interim data from Phase 1b/2a study of AG019 ActoBiotics for... 
Via Benzinga
Provention Bio, Inc. (NASDAQ:PRVB) Long Term Investor Notice: Investigation over Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/22/2021 -- An investigation was announced over possible breaches of fiduciary duties by certain directors of Provention Bio, Inc. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Provention Bio, inc (PRVB) Q2 2021 Earnings Call Transcript
PRVB earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
PRVB Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 20, 2021
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
From The Law Offices of Frank R. Cruz
Via Business Wire
Is Provention Bio a Bad News Buy?
There's a good case this biotech stock is now at least somewhat undervalued. 
Via The Motley Fool
Exposures Product Safety
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
NASDAQ:PRVB Investor Notice: Deadline on July 20, 2021 in Lawsuit Against Provention Bio, Inc.
San Diego, CA -- (SBWIRE) -- 07/08/2021 -- The Shareholders Foundation announced that a deadline is coming up on July 20, 2021 in the lawsuit filed for certain investors of Provention Bio, Inc.... 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Mid-Afternoon Market Update: Dow Tumbles 300 Points; Advaxis Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.86% to 34,488.53 while the NASDAQ fell 0.08% to 14,626.98. The S&P also fell, dropping 0.48% to 4,331.47. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why Provention Bio Stock Is Diving Today
The company's latest letter from the FDA wasn't what investors had hoped for. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Advaxis (NASDAQ:ADXS) shares increased by 43.13% to $0.68 during Tuesday's regular session. The current volume of 106.3 million shares is 1084.49% of Advaxis... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday.... 
Via Benzinga
Mid-Day Market Update: Gold Rises Over 1%; Provention Bio Shares Plunge
Midway through trading Tuesday, the Dow traded down 1.09% to 34,408.75 while the NASDAQ rose 0.01% to 14,641.07. The S&P also fell, dropping 0.60% to 4,326.41. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
42 Stocks Moving In Tuesday's Mid-Day Session
Gainers Orbsat Corp. (NASDAQ: OSAT) shares jumped 74% to $9.47. BSQUARE Corporation (NASDAQ: BSQR) shares jumped 48.2% to $5.90 after dropping around 10% on Friday. Bridgeline... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower; ISM Services PMI Falls In June
Following the market opening Tuesday, the Dow traded down 0.62% to 34,569.49 while the NASDAQ rose 0.19% to 14,667.72. The S&P also fell, dropping 0.27% to 4,340.67. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ:... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 51 companies reached new 52-week lows. Noteworthy Highlights: China Life Insurance Co (NYSE:LFC) was the largest company by market cap to set a new... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Advaxis (NASDAQ:ADXS) stock rose 46.9% to $0.69 during Tuesday's pre-market session. The market value of their outstanding shares is at $100.9 million. Axcella... 
Via Benzinga
Provention Bio's Teplizumab Application Receives CRL For Type-1 Diabetes; Stock Drops
The FDA has issued a Complete Response Letter (CRL) to Provention Bio Inc's (NASDAQ: PRVB) teplizumab marketing application seeking approval for the delay... 
Via Benzinga
Exposures Product Safety
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Odonate Therapeutics, Inc. (NASDAQ: ODT) shares rose 38.3% to $4.80 in pre-market trading following 13G from Ikarian Capital showing a 5.2% stake in the company. BSQUARE... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.